Aligos Therapeutics Inc (NASDAQ: ALGS) on Tuesday, plunged -8.05% from the previous trading day, before settling in for the closing price of $20.12. Within the past 52 weeks, ALGS’s price has moved between $6.76 and $30.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 46.14% over the past five years. The company achieved an average annual earnings per share of 70.31%. With a float of $2.54 million, this company’s outstanding shares have now reached $2.88 million.
Let’s look at the performance matrix of the company that is accounted for 66 employees. In terms of profitability, gross margin is 65.67%, operating margin of -1577.26%, and the pretax margin is -1278.62%.
Aligos Therapeutics Inc (ALGS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Aligos Therapeutics Inc is 29.21%, while institutional ownership is 49.89%.
Aligos Therapeutics Inc (ALGS) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -5.5 earnings per share (EPS) for the period topping the consensus outlook (set at -6.75) by 1.25. Wall Street market experts anticipate that the next fiscal year will bring earnings of -3.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.31% per share during the next fiscal year.
Aligos Therapeutics Inc (NASDAQ: ALGS) Trading Performance Indicators
Aligos Therapeutics Inc (ALGS) is currently performing well based on its current performance indicators. A quick ratio of 3.81 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -13.35, a number that is poised to hit -2.50 in the next quarter and is forecasted to reach -11.92 in one year’s time.
Technical Analysis of Aligos Therapeutics Inc (ALGS)
Aligos Therapeutics Inc (NASDAQ: ALGS) saw its 5-day average volume 0.85 million, a positive change from its year-to-date volume of 78234.0. As of the previous 9 days, the stock’s Stochastic %D was 75.01%. Additionally, its Average True Range was 2.69.
During the past 100 days, Aligos Therapeutics Inc’s (ALGS) raw stochastic average was set at 64.94%, which indicates a significant increase from 60.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 165.91% in the past 14 days, which was higher than the 149.54% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.50, while its 200-day Moving Average is $15.33. Nevertheless, the first resistance level for the watch stands at $24.01 in the near term. At $29.52, the stock is likely to face the second major resistance level. The third major resistance level sits at $34.20. If the price goes on to break the first support level at $13.82, it is likely to go to the next support level at $9.14. The third support level lies at $3.63 if the price breaches the second support level.
Aligos Therapeutics Inc (NASDAQ: ALGS) Key Stats
Market capitalization of the company is 66.38 million based on 3,588K outstanding shares. Right now, sales total 15,530 K and income totals -87,680 K. The company made 1,270 K in profit during its latest quarter, and -19,260 K in sales during its previous quarter.
